BLAINJECTIONINJECTABLEPriority Review
Approved
Apr 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
7
Mechanism of Action
X-linked hypophosphatemia is caused by excess fibroblast growth factor 23 (FGF23) which suppresses renal tubular phosphate reabsorption and the renal production of 1,25 dihydroxy vitamin D. Burosumab-twza binds to and inhibits the biological activity of FGF23 restoring renal phosphate reabsorption…
Clinical Trials (5)
Effective Dosing of Burosumab in XLH
Started Sep 2025
120 enrolled
X-linked Hypophosphatemia (XLH)
Anti-FGF23 (Burosumab) in Adult Patients With XLH
Started Jan 2021
36 enrolled
X-linked Hypophosphatemia
Burosumab for CSHS
Started Jul 2019
1 enrolled
Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)Epidermal Nevus Syndrome
Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets
Started Jan 2018
1 enrolled
HypophosphatemiaHypophosphatemic RicketsPain, Chronic
Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH
Started Sep 2016
61 enrolled
X-Linked Hypophosphatemia